A survey by Ipsos, sponsored by GSK, found that while 63% of adults aged 50 years or over in Singapore were aware of shingles, only 29% recognised that 1 in 3 may develop the disease in their lifetime ...

Oxylipins, particularly arterial 15-keto PGF2a, were identified as significant predictors of 5-year mortality in HFpEF patients. The study utilized high-performance liquid chromatography and mass ...

Pulmonary arterial hypertension (PAH) is a rare condition that's difficult to treat. The hallmarks of the disease—narrowing ...

Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial ...

The U.S. Food and Drug Administration (FDA) approved sotatercept in March 2024 for treatment of pulmonary hypertension, ...

Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within ...

Patients were better able to keep exercising and avoid unexpected hospitalizations MONDAY, Oct. 6, 2025 (HealthDay News) — A recently approved injectable drug can significantly stall deteriorating ...

For recently diagnosed pulmonary arterial hypertension (PAH), adding sotatercept (Winrevair) to standard care lowered the risk of clinical worsening, the randomized HYPERION trial showed. Among 320 ...

Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within ...

New American Heart Association guidelines redefine hypertension, lowering target blood pressure levels. The category of prehypertension is removed, replaced by 'elevated blood pressure'. Lifestyle ...